Jerke U, et al. Targeting cathepsin C in PR3-ANCA vasculitis. J Am Soc Nephrol 2022; 33:936–947. doi: 10.1681/ASN.2021081112
Rhee RL, et al. Trends in long-term outcomes among patients with antineutrophil cytoplasmic antibody-associated vasculitis with renal disease. Arthritis Rheumatol 2016; 68:1711–1720. doi: 10.1002/art.39614
Wallace ZS, et al. Nationwide trends in hospitalizations and in-hospital mortality in granulomatosis with polyangiitis (Wegener's). Arthritis Care Res (Hoboken) 2017; 69:915–921. doi: 10.1002/acr.22976
Mohammad AJ, et al. Severe infection in antineutrophil cytoplasmic antibody-associated vasculitis. J Rheumatol 2017; 44:1468–1475. doi: 10.3899/jrheum.160909
Charlier C, et al. Risk factors for major infections in Wegener granulomatosis: Analysis of 113 patients. Ann Rheum Dis 2009; 68:658–663. doi: 10.1136/ard.2008.088302
Goupil R, et al. Lymphopenia and treatment-related infectious complications in ANCA-associated vasculitis. Clin J Am Soc Nephrol 2013; 8:416–423. doi: 10.2215/CJN.07300712
Jayne DRW, et al. Avacopan for the treatment of ANCA-associated vasculitis. N Engl J Med 2021; 384:599–609. doi: 10.1056/NEJMoa2023386